Innovative Medicine

STELARA when used as a first-line therapy was associated with longer time in clinical remission or clinical response, including the postponing of surgery, among adult patients with moderately to severely active ulcerative colitis compared with usage as a second- or third-line therapy in a modelled analysis Bio-naïve patients with moderately to severely active Crohn’s disease started on STELARA showed higher rates of persistence at one year compared to adalimumab in a retrospective real-world evidence study

Recommendation informed by Phase 3 findings showing a booster increased protection to 94 percent against moderate to severe/critical COVID-19 in the U.S. Johnson & Johnson COVID-19 vaccine, when given as a booster or primary dose, was generally well-tolerated FDA to decide whether to authorize a booster dose in the coming days

Canadians living with PAH, a rare disease for which there is no cure, now have a new treatment option

Combination of clinical data and real-world evidence underscores need for earlier, accurate PAH diagnosis and timelier introduction of appropriate therapy

Application utilizes extrapolation-based strategy across existing breadth of STELARA data in patients living with this chronic inflammatory disease

Early-stage research suggests potential to prevent and treat all dengue serotypes With no treatments available, dengue infects up to 400 million people each year and the pace of outbreaks is increasing.[1] This research builds on Johnson & Johnson’s work to advance science against emerging and entrenched global public health threats

Submission includes data showing a booster increased protection to 94 percent against moderate to severe/critical COVID-19 in the U.S. Substantial increase in immune response when booster was given at six months The Company’s single-shot vaccine has demonstrated strong and long-lasting protection and durable immune responses in clinical studies

First examination of safety events in the 60 and over sub-population across STELARA indications, including inflammatory bowel disease where relatively little biologics safety data exists, are generally consistent with placebo Janssen presents 13 abstracts, including four oral presentations and two late breakers

Phase 2b CYPRESS study met all primary and secondary endpoints